Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020. Biosimilars or follow-on-biologics are the copied version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Biosimilar medicines have witnessed growth over the past five and six years.
Regulations for this biologic medical product plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the global biosimilars market. Regulations in the European union are considered benchmark around the world, as the guidelines proposed are most stringent for validation and commercialization of biosimilars. High profitability is the attractive aspect that is enticing companies to invest in the biosimilars industry.
Geographically, Biosimilars market is segmented into North America, Europe, Asia-Pacific and LAMEA. Due to favorable regulatory policies designed by the European Medical Association, the European market has been maximizing on the market. Asia-Pacific and LAMEA market would witness a substantial rise in the use of biosimilars, as the demand for cost effective treatment is growing due to the prevalence of chronic diseases. Collaboration with local players would be a key opportunity that could be fully explored by the biosimilars manufacturers in developing economies. Many companies such as Amgen and Novartis are collaborating with Asian players to gain a foothold in the biopharmaceutical market.
Europe was the first region to draft guidelines for approval of biosimilars in 2006. Nevertheless, in 2008, the first biosimilars version of Granulocyte colony-stimulating factor (G-CSF) was introduced in the European Union under the regulatory guidance of European Medical Association (EMA). Currently, there are three biosimilar versions of G-CSF available in the European market, namely Ratiograstim/Tevagrastim/Biograstim, Zarzio/Filgrastim Hexal and Nivestim/Pliva/Mayne filgrastim. Adding to the G-CSF biosimilars, the insulin biosimilars also showcase tremendous potential in the future.
BIOSIMILARS MARKET KEY BENEFITS
The report on Biosimilars market 2020 is segmented in a strategic division to gain deeper insights into the market dynamics, size and understand the competitive environment of the overall market
Financial market forecast is provided for the next eight years by considering 2013 as the base year
Comprehensive and quantitative data analysis about changing trends, intensifying competition and opportunities in biosimilars market 2020 are provided to make better business decisions
Porters Five Forces model and SWOT analysis of the overall Biosimilars industry is provided to help stakeholders gain strategic insights of the market
Deep dive analysis of key players and strategies adopted by them are expounded to provide valuable information on the top contenders in the market
Identification of key investment pockets for the market is strategically dealt to assist the stakeholders
BIOSIMILARS MARKET KEY DELIVRABLES
Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography.
Monoclonal Antibodies (MAb) Technology
Recombinant DNA Technology (rDNA technology)
Nuclear magnetic resonance (NMR) technology
Recombinant Non-Glycosylated Protein
Human Growth Hormone
Granulocyte colony stimulating factor (G-CSF)
Recombinant Glycosylated Protein
Chemotherapy induce Anaemia
Chronic and autoimmune diseases
Rheumatoid arthritis (RA)
Growth hormone deficiencies
Contract Research and Manufacturing Services (CRAMS)
Global biosimilars/follow-on-biologics market in this report is segmented based on their functional bonding in which they are found such as glycosylated and non-glycosylated. Several pharmaceutical manufacturers are exploiting the lucrative opportunities available in this market. Presently, reference biologics are protected by IP (Intellectual Property) rights; however, the property protections for blockbuster drugs will soon expire, this will open up a platform for biosimilars manufacturers to gain dominance. Growing demand for over-the-counter (OTC) and prescription-based drugs would also cement the growth of the biosimilars industry in developing economies. Biosimilars versions of some monoclonal antibodies and granulocyte colony stimulating factors commercialized in the market have gained substantial foothold in the market in terms of revenue and growth. These medicines have outperformed their reference versions in terms of cost, performance and output. After successful market entry, the players operating in this market are now assured of its potential. This has lead to increase in their interest for the research and development of novel biosimilar versions of the blockbuster drugs, which have soon to expire property protections. The biosimilars market would have a double digit growth rate and garner billions of dollars from the reference biopharmaceutical industry during 2013-2020. Developing economies such as China and India would act as the principle contributors to the growth of the biosimilar industry. This is due to the increase in healthcare expenditure, change in the quality of lifestyle and prevalence of chronic diseases in these regions. Additionally, under-developed economies such as those in Africa are also allowing biosimilars to be commercialized under the guidance of government regulations. Demand for biosimilar drugs in developed economies is still yet to gain popularity, as the consumer base in these countries shows an inclination towards branded drugs instead of biosimilars; hence, the biosimilars market is expecting sluggish growth in developed countries during the analysis period.
Medical implants are medical devices or tissues that are surgically transplanted inside the body. These implants are used to replace or support any damaged body organs to enhance function of any body organ or to detect errors in normal body functioning. These can be either placed permanently or temporarily in human body and can be removed when they are no longer needed.
Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market.
Internet of things (IoT), comprising components such as devices, network connectivity, electronics system and software, is basically the networking of connected devices or things to transmit the data between them without human intervention.
The dental consumables are the products used by patients for the treatment of dental disorders such as tooth restoration, problems associated with gingival tissues and dental impairments. The goal of this report includes market estimation that covers industry analysis with its share and size. Moreover, market overview gives an insight on the global dental consumable market growth, opportunities, restraints and key drivers of the market as well as market analysis based on geography.
Cell separation technologies involve the separation of cells from a heterogeneous cell mixture according to their intracellular or extracellular properties. Cell separation has gained importance in the fields of medicine and biology as it is an essential component of cellular therapy and disease diagnosis. The recent expansion of the field of cell separation is linked to an increase the mortality rate due to chronic diseases as majority of these diseases can be treated using cell-based therapies. A pinpoint analysis of the global cell separation technologies market focuses on various aspects of the market such as market trends, market drivers, restraints and opportunities.
Spinal intervention provides minimally invasive treatment for spine and nerve related painful conditions. The most frequently treated diseases are sciatica, herniated discs, arthritis of the spine, vertebral fracture, neuropathic or nerve pain in hands and legs, narrowing of the spinal canal, post-herpes neuralgia, trigeminal neuralgia, refractory pelvic pain, back or leg pain after back surgery, vascular diseases related pain, phantom limb pain and terminal cancer pain.